10 October 2024
IXICO plc
("IXICO" or the
"Company")
Exercise of Options &
Director/PDMR Purchase
IXICO plc (AIM: IXI), the medical
imaging advanced analytics company delivering insights in
neuroscience, announces that it has issued,
conditional on admission, 1,695,717 new ordinary shares of 1 pence
each in the capital of the Company ("Ordinary Shares"), pursuant to the
exercise of share options ("Options") under the Company's 2014 EMI
Share Option Plan (the "2014
Plan"). 200,000 of these Options were exercised by Grant
Nash, Chief Financial Officer and PDMR of the Company.
All tax and costs were paid
separately by Mr Nash with no sale of Ordinary Shares
required. Following this exercise, Mr Nash's holding has
increased to 400,000 Ordinary Shares representing approximately
0.8% of the current Issued Share Capital of the Company.
In addition, Mark Warne, Chair of
the Company has purchased 52,685 Ordinary Shares in the
market. Following this purchase, Mr Warne's holding has
increased to 72,335 representing approximately 0.14% of the current
Issued Share Capital of the Company.
The new Ordinary Shares will rank
pari passu with the existing Ordinary Shares in issue and
application has been made for the new Ordinary Shares to be
admitted to trading on the AIM Market of the London Stock Exchange
("Admission"). Admission is
expected to occur, and dealings in the new Ordinary Shares
commence, at 8:00 a.m. on 14 October 2024.
Total Voting Rights
Following Admission, the Company
will have 50,047,090 Ordinary Shares in issue. This figure of
50,047,090 may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change of their interest in, the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
For
further information please contact:
|
IXICO plc
|
+44 (0) 20 3763 7499
|
|
Bram Goorden, Chief Executive
Officer
Grant Nash, Chief Financial
Officer
|
|
|
|
|
|
Cavendish Capital Markets Limited
(Nominated adviser and sole broker)
|
+44 (0) 20 7220 0500
|
|
Giles Balleny / Dan Hodkinson
(Corporate Finance)
|
|
|
|
Nigel Birks (Life Sciences
Specialist Sales)
Harriet Ward (Corporate
Broking)
Michael F Johnson / Tamar Cranford
Smith (Sales)
|
|
|
|
|
|
|
|
|
|
| |
About IXICO
IXICO is dedicated to
delivering insights in neuroscience to help transform the
advancement of investigational therapies for neurological diseases,
such as Huntington's disease, Parkinson's disease and Alzheimer's
disease. The Company's purpose is to advance medicine and human
health by turning data into clinically meaningful information,
providing valuable new insights in neuroscience by supporting
pharmaceutical companies across all phases of CNS clinical
research. IXICO's goal is to be a leading advocate of
artificial intelligence in medical image analysis.
IXICO has developed and
deployed breakthrough data analytics, at scale, through its remote
access technology platform, to improve the return on investment in
drug development and reduce risk and uncertainty in clinical trials
for the Company's pharmaceutical clients.
More information is available
on www.IXICO.com and follow us on Twitter @IXICOnews
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
Grant Nash
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Financial Officer and
PDMR
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
IXICO plc
|
|
b)
|
LEI
|
2138005M1F59O6HWSA97
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary shares in IXICO
plc
ISIN: GB00BFXR4C20
|
|
b)
|
Nature of the transaction
|
Exercise of Options
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
1 pence
|
200,000
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
9 October 2024
|
|
f)
|
Place of the transaction
|
Outside of a trading
venue
|
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
Mark Warne
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chair and
PDMR
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
IXICO plc
|
|
b)
|
LEI
|
2138005M1F59O6HWSA97
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary shares in IXICO
plc
ISIN: GB00BFXR4C20
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
9.5 pence
9.48 pence
|
26,315
26,370
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
52,685 Ordinary Shares
9.49 pence
|
|
e)
|
Date of the transaction
|
9 October 2024
10 October
|
|
f)
|
Place of the transaction
|
LSE/AIMX
|